KRAS and colorectal cancer: An oncogenic missense mutation p.V600E in BRAF, a downstream signalling molecule of KRAS, has been identified in around 5% of colorectal cancer tumors, though somewhat higher in this series at 10%, and results in activation of the MAPK signalling pathway [14].